Efficacy of caspofungin and posaconazole in a murine model of disseminated Exophiala infection

Medical Mycology

Volumn 45, Issue 8, 2007, Pages 685-689

  Rivard, Robert G ^a   McCall, Suzanne ^a   Griffith, Matthew E ^a   Hawley, Joshua S ^a   Ressner, Roseanne A ^a   Borra, Himabindu ^a   Moon, James E ^a   Beckius, Miriam L ^a   Murray, Clinton K ^a   Hospenthal, Duane R ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

Caspofungin; Exophiala; Mouse; Phaeohyphomycosis; Posaconazole

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; CYCLOPHOSPHAMIDE; POSACONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG EFFICACY; EXOPHIALA; EXOPHIALA PHAEOMURIFORMIS; FEMALE; IMMUNE DEFICIENCY; INSTITUTE FOR CANCER RESEARCH MOUSE; KIDNEY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHAEOHYPHOMYCOSIS; SURVIVAL RATE;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; BRAIN; DISEASE MODELS, ANIMAL; ECHINOCANDINS; EXOPHIALA; FEMALE; IMMUNOCOMPROMISED HOST; KIDNEY; MICE; MICE, INBRED ICR; MYCOSES; SURVIVAL ANALYSIS; TRIAZOLES;

ANIMALIA; EXOPHIALA; MURINAE; MUS;

EID: 36348939208     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780701390157     Document Type: Article

References (24)

1. Bodey, GP. (1988) The emergence of fungi as major hospital pathogens. J Hosp Infect, 11, pp. 411-426.
2. Clark, TA and Hajjeh, RA. (2002) Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis, 15, pp. 569-574.
3. Mok, WY and da Silva, Barreto MS. (1984) Mycoflora of the human dermal surfaces. Can J Microbiol, 30, pp. 1205-1209.
4. Perfect, JR and Schell, WA. (1996) The new fungal opportunists are coming. Clin Infect Dis, 22, pp. S112-S118.
5. Rees, JR, Pinner, RW and Hajjeh, RA (1998) The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis, 27, pp. 1138-1147.
6. Silveira, F. and Nucci, M. (2001) Emergence of black moulds in fungal disease: Epidemiology and therapy. Curr Opin Infect Dis, 14, pp. 679-684.
7. Brandt, ME and Warnock, DW. (2003) Epidemiology, clinical manifestations, and therapy of infections caused by dematiaceous fungi. J Chemother, 15, pp. 36-47.
8. Perfect, JR, Schell, WA and Cox, GM. (1992) Phaeohyphomycoses. Medical Mycology, pp. 271-282. Lea &Febiger, Philadelphia
9. Nucci, M., Akiti, T. and Barreiros, G. (2002) Nosocomial outbreak of Exophiala jeanselmei fungemia associated with contamination of hospital water. Clin Infect Dis, 34, pp. 1475-1480.
10. Nucci, M., Akiti, T. and Barreiros, G. (2001) Nosocomial fungemia due to Exophiala jeanselmei var. jeanselmei and a Rhinocladiella species: Newly described causes of bloodstream infections. J Clin Microbiol, 39, pp. 514-518.
11. Revankar, SG, Sutton, DA and Rinaldi, MG. (2004) Primary central nervous system phaeohyphomycosis: A review of 101 cases. Clin Infect Dis, 38, pp. 206-216.
12. Revankar, SG, Patterson, JE and Sutton, DA (2002) Disseminated phaeohyphomycosis: Review of an emerging mycosis. Clin Infect Dis, 34, pp. 467-476.
13. Rinaldi, MG. (1996) Phaeohyphomycosis. Dermatol Clin, 14, pp. 147-153.
14. National Committee for Clinical Laboratory Standards (NCCLS) (2002) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. NCCLS, NCCLS, Wayne, PA
15. González, GM, Tijerina, R. and Najvar, LK (2001) Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob Agents Chemother, 45, pp. 1854-1859.
16. Hajdu, R., Thompson, R. and Sundelof, JG (1997) Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother, 41, pp. 2339-2344.
17. Sugar, AM and Liu, X. (1996) In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother, 40, pp. 1314-1316.
18. Perfect, JR, Marr, KA and Walsh, TJ (2003) Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis, 36, pp. 1122-1131.
19. Negroni, R., Helou, SH and Petri, N. (2004) Case study: Posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera. Clin Infect Dis, 38, pp. e15-e20.
20. Poeta, M Del, Schell, WA and Perfect, JR. (1997) In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother, 41, pp. 1835-1836.
21. Petraitiene, R., Petraitis, V. and Groll, AH (2002) Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: Pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother, 46, pp. 12-23.
22. Trinh, JV, Steinbach, WJ and Schell, WA (2003) Cerebral phaeohyphomycosis in an immunodeficient child treated medically with combination antifungal therapy. Med Mycol, 41, pp. 339-345.
23. Sabatelli, F., Patel, R. and Mann, PA (2006) In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother, 50, pp. 2009-2015.
24. Graybill, JR, Najvar, LK and Johnson, E. (2004) Posaconazole therapy of disseminated phaeohyphomycosis in a murine model. Antimicrob Agents Chemother, 48, pp. 2288-2291.